文献速递血栓与止血

大型塞尔维亚家系中凝血酶原贝尔格莱德突变的临床与生化特征:对抗凝血酶抵抗机制的新见解

Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism.
PubMed 文献 · J Thromb Haemost · 2017-02-24

研究了一个携带凝血酶原贝尔格莱德突变(c.1787G>A)的塞尔维亚家系,共19名成员,其中10名为突变携带者。6名携带者发生血栓栓塞事件,首次血栓中位年龄26.5岁,年发生率2.2%。所有携带者凝血酶原活性显著降低且内源性凝血酶生成潜力显著升高,而D-二聚体和F1+2片段两组相似。

要点

  • 凝血酶原贝尔格莱德突变携带者凝血酶原活性显著低于非携带者,可区分两组。
  • 携带者内源性凝血酶生成潜力显著升高,提示血液高凝状态。
  • 10名携带者中6名发生血栓栓塞,首次血栓中位年龄26.5岁。

核心结论

  • 凝血酶原贝尔格莱德突变虽罕见,但在所研究家系中表现为强血栓形成倾向且血栓早发。
  • 作者认为,凝血酶原活性降低可能是检测血栓患者中该突变的简单筛查试验。

研究设计与样本

  • 对19名塞尔维亚家系成员进行研究,其中10名为c.1787G>A突变携带者。
  • 对所有受试者确定临床表型并检测止血参数。

主要发现

  • 10名突变携带者中6名发生血栓栓塞事件,主要为深静脉和肠系膜静脉血栓。
  • 首次血栓事件的中位年龄为26.5(12-41)岁,首次血栓年发生率为2.2%。
  • 所有突变携带者凝血酶原活性较非携带者显著降低,清晰区分两组。
  • 突变存在与否不影响血浆凝血酶原抗原水平。
  • 所有携带者内源性凝血酶生成潜力较非携带者显著升高,提示血液高凝状态。

临床怎么用

  • 作者认为,凝血酶原活性降低可能是检测血栓患者中该突变的简单筛查试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Prothrombin Belgrade mutation leads to antithrombin resistance. Clinical and biochemical phenotypes in a large family with this mutation were investigated. In carriers, we detected decreased factor II activity and increased endogenous thrombin potential. Prothrombin Belgrade mutation represents a strong prothrombotic risk factor. SUMMARY: Background The recently reported c.1787G>A mutation in the prothrombin gene leads to Arg596Gln replacement in the protein molecule (prothrombin Belgrade). This substitution impairs binding of antithrombin to thrombin and results in inherited thrombophilia, known as antithrombin resistance. Objectives We aimed to elucidate the clinical and biochemical characteristics of thrombophilia associated with antithrombin resistance in a large Serbian family with the prothrombin Belgrade mutation. Patients and methods Nineteen family members were investigated, among whom 10 were carriers of the c.1787G>A mutation. In all subjects the clinical phenotype was determined and laboratory investigations of hemostatic parameters were performed. Results Six out of the 10 mutation carriers developed thromboembolic events, mainly deep venous and mesenteric vein thrombosis. The median age of the first thrombotic event was 26.5 (12-41) years, whereas the incidence rate of first thrombosis was 2.2% per year. In all mutation carriers prothrombin activity was significantly decreased in comparison with non-carriers, clearly distinguishing each group. However, the presence of the mutation did not affect the prothrombin antigen level in plasma. The endogenous thrombin potential was significantly increased in all carriers in comparison with non-carriers, indicating the presence of blood hypercoagulability. Interestingly, levels of D-dimer and the F1+2 fragment were similar in both groups. Conclusions Although rare, the prothrombin Belgrade mutation represents strong thrombophilia with early onset of thrombosis in the investigated family. According to our results, decreased prothrombin activity may be a simple screening test for detection of this mutation in thrombotic patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Miljic P, Gvozdenov M, Takagi Y, et al. Clinical and biochemical characterization of the prothrombin Belgrade mutation in a large Serbian pedigree: new insights into the antithrombin resistance mechanism. J Thromb Haemost. 2017. PMID: 28075532. doi:10.1111/jth.13618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。